A detailed history of Geode Capital Management, LLC transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,110,085 shares of ELEV stock, worth $732,656. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,110,085
Previous 1,031,576 7.61%
Holding current value
$732,656
Previous $2.79 Million 76.09%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.56 - $3.02 $43,965 - $237,097
78,509 Added 7.61%
1,110,085 $666,000
Q2 2024

Aug 09, 2024

BUY
$2.35 - $5.17 $1.61 Million - $3.53 Million
683,143 Added 196.06%
1,031,576 $2.79 Million
Q1 2024

May 13, 2024

BUY
$0.59 - $5.13 $69,795 - $606,863
118,297 Added 51.4%
348,433 $1.79 Million
Q3 2023

Nov 13, 2023

BUY
$0.65 - $1.56 $61,081 - $146,594
93,971 Added 69.01%
230,136 $151,000
Q2 2023

Aug 11, 2023

BUY
$1.4 - $5.06 $8,098 - $29,272
5,785 Added 4.44%
136,165 $206,000
Q1 2023

May 15, 2023

BUY
$0.75 - $2.55 $30,027 - $102,094
40,037 Added 44.32%
130,380 $247,000
Q4 2022

Feb 13, 2023

SELL
$0.89 - $1.19 $252 - $337
-284 Reduced 0.31%
90,343 $85,000
Q3 2022

Nov 14, 2022

BUY
$1.03 - $1.53 $66,291 - $98,472
64,361 Added 245.04%
90,627 $102,000
Q1 2022

May 13, 2022

BUY
$2.34 - $6.41 $12,273 - $33,620
5,245 Added 24.95%
26,266 $66,000
Q4 2021

Feb 11, 2022

BUY
$4.15 - $8.86 $36,789 - $78,543
8,865 Added 72.93%
21,021 $126,000
Q3 2021

Nov 12, 2021

BUY
$7.66 - $16.11 $93,114 - $195,833
12,156 New
12,156 $94,000

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $15.4M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.